Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919773 · ClinicalTrials.gov registry record · Phase 1
IVIG (Gamunex-C) Treatment Study for POTS Subjects
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03919773 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT03919773, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the symptomatic benefits of immunomodulatory treatment with IVIG for POTS (postural tachycardia syndrome) patients with evidence of autoimmunity.
Interventions
- DRUG IVIG
- DRUG Albumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919773
The ClinicalTrials.gov registry entry for NCT03919773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IVIG is the first listed.
NCT03919773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919773 about?
NCT03919773 is a clinical study titled "IVIG (Gamunex-C) Treatment Study for POTS Subjects". The purpose of this trial is to evaluate the symptomatic benefits of immunomodulatory treatment with IVIG for POTS (postural tachycardia syndrome) patients with evidence of autoimmunity.
What is the current status of trial NCT03919773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-10-29. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT03919773?
The interventions under investigation include: IVIG (DRUG), Albumin (DRUG).
Who is sponsoring clinical trial NCT03919773?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.